Wart war: blood clot vs vitamin jab – which works best?
NCT ID NCT07543926
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests two injection treatments for common warts: one using a patient's own blood components (platelet-rich fibrin) and the other using vitamin D. About 70 adults with warts will receive one of the two injections. The goal is to see which treatment shrinks warts more and keeps them from coming back.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 70 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Apr 2026
An estimate. Start dates often move.
- Expected to finish
-
Dec 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * \- Age more than or equal to 18 years * Clinically and dermoscopically confirmed Common warts of both sex * patient not receiving previous treatment at least one month before recruitment in our study * Single or multiple lesions suitable for injection. Exclusion Criteria: * Chronic Systemic desise (DM , HTN , Autoimmune , immunosuppressive disorders eg , lupus , renal or hepatic failure ) or Hematologic Conditions (anemia : hemoglobin level below 10 g/dl , thrombocytopenia : platelet count below 150,000 /µL ) Infectious Diseases , Local bacterial or fungal infection at the lesions . Pregnancy, Lactation , patients who has hypersensitivity of vitamin D .
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Common warts (verruca vulgaris) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Sohag University
Sohag, Egypt
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a blister beetle extract banish common warts? phase 3 trial investigates
- New hope for stubborn warts: extended treatment shows promise
- Wart war: vitamin D3 or acyclovir injections – which works better?
- New gel could zap away common warts in just weeks
- Could a yeast extract injection finally banish common warts?